Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

NCT04227210 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV vaccine MV-012-968 (dosage #1)
BIOLOGICAL: RSV vaccine MV-012-968 (dosage #2)

Sponsor

Meissa Vaccines, Inc.